-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20

Benzinga·08/13/2026 13:56:24
Listen to the news
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.